Marinus Pharmaceuticals (MRNS) PT Lowered to $35 at Truist Securities on Trial Delay, Analyst Maintains Confidence in Ganaxolone
Tweet Send to a Friend
Truist Securities analyst Joon Lee lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $35.00 (from $40.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
